Skip to main content
Caplight Logo









Alzprotect

Alzprotect

Private
LilleHealthcare & Life Scienceshttps://alzprotect.com/

Last Round

Grant

Jun 1, 2022

Total Funding Raised

$26.29M

Company Overview

Alzprotect is a biopharmaceutical company that develops drug candidates for the treatment of neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, and Progressive Supranuclear Palsy.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Revenue Share, Government Contracts

AI Layer

Non-AI

Keywords

neurodegenerative disease drugProgressive Supranuclear PalsyPSP treatmentAZP2006Ezeprogindsmall molecule drugtauopathy treatmentphase 2 clinical trialclinical stage biotechorphan drugOrphan Drug DesignationAlzheimer's disease drugfirst-in-class therapeuticbiotech licensingprogranulin modulationParkinson's disease druglysosomal dysfunction treatmentneuroinflammation therapy

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Alzprotect Comparables

Compare Alzprotect with similar companies based on industry and business-model similarity.

Alzprotect comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Asceneuron
85%
Transposon Therapeutics
79%
Oligomerix, Inc.
78%

Alzprotect Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantJun 1, 2022
Corporate FundingJan 1, 2022
Series BJan 23, 2018
Series A ExtensionSep 21, 2016
DebtJun 11, 2014
Series A
Jun 11, 2014

Key People

Founding team and executive leadership

Philippe Verwaerde

CEO

Executive Team

Olivier Defert

COO

Executive Team

Alzprotect Investors

Notable investors and investment history

Alzprotect investors
InvestorRounds
XerysCorporate Funding, Series B
Invest SecuritiesSeries A Extension
FinorpaSeed
Siparex GroupCorporate Funding, Seed, Series A, Series A Extension
The Michael J. Fox Foundation for Parkinson's ResearchGrant
Finovam GestionCorporate Funding, Series A, Series A Extension
BpifranceDebt

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 1, 2025

    Monthly visitors increased 744% MoM, from 59 to 498.

  • Aug 12, 2023

    Grew 27% QoQ, from 11 to 14 employees.

Alzprotect Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Alzprotect Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Alzprotect's valuation, stock price, and market status.

Firmographic Details

HeadquartersLille
Employee Range9
Year Founded2007
Last FundingJun 1, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?